Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration

Trial Profile

Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
  • Indications Bone disorders
  • Focus Therapeutic Use
  • Sponsors NextGen Sciences
  • Most Recent Events

    • 05 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
    • 05 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
    • 21 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top